Rofo 2024; 196(08): 850-851
DOI: 10.1055/a-2272-5346
The Interesting Case

18F-FDG PET/CT in assessment of paraneoplastic cerebellar degeneration as the first sign of occult fallopian tube serous cystadenocarcinoma: Case report

18F-FDG PET/CT zur Beurteilung einer paraneoplastischen Kleinhirndegeneration als erstes Zeichen eines okkulten serösen Zystadenokarzinoms des Eileiters: Fallbericht
1   Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Gregor Schweighofer-Zwink
1   Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
2   Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Gundula Rendl
1   Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Christian Pirich
1   Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Mohsen Beheshti
1   Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
› Institutsangaben

Background

18F-FDG PET/CT may be considered as a useful tool for the assessment of primary tumor detection in patients with paraneoplastic neurological syndromes (Opalińska, M, et al. J Clin Med, 2022. 11(6)). Besides, 18F-FDG PET/CT is a fast-track access to additional diagnostics among pre-treatment of gynecological cancers (Sponholtz, S.E., et al., Acta Obstet Gynecol Scand, 2020. 99(2): p. 186–195. Dejanovic, D., et al. Seminars in Nuclear Medicine, 2021. 51(6): p. 593–610.) Paraneoplastic neurological syndromes (PNS) are rare heterogeneous groups of neurological disorders associated with an underlying malignancy. (Rosenfeld, M.R. et al. Neurologic Clinics, 2018. 36(3): p. 675–685. Dalmau, J. et al. The Lancet Neurology, 2008. 7(4): p. 327–340). Paraneoplastic cerebellar degeneration (PCD) accounts for about one-fourth of PNS, which more frequently involves the cerebellum (Vogrig, A., et al. Journal of Neurology, 2020. 267(1): p. 26–35.) Diagnosis of PNS is challenging which may cause misdiagnosis and delay of treatment management may occur. Therefore, accurate and early identification of clinically suspected tumors causing PNS is crucial for optimal disease management and patient outcome (Maskery, M.P., et al. Front Neurol, 2017. 8: p. 238.).



Publikationsverlauf

Eingereicht: 29. August 2023

Angenommen nach Revision: 19. Februar 2024

Artikel online veröffentlicht:
16. April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany